These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 15322948)

  • 1. Molecular modeling of the von Willebrand factor A2 Domain and the effects of associated type 2A von Willebrand disease mutations.
    Sutherland JJ; O'Brien LA; Lillicrap D; Weaver DF
    J Mol Model; 2004 Aug; 10(4):259-70. PubMed ID: 15322948
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of mutations in the von Willebrand factor A2 domain on ADAMTS13-dependent proteolysis.
    Hassenpflug WA; Budde U; Obser T; Angerhaus D; Drewke E; Schneppenheim S; Schneppenheim R
    Blood; 2006 Mar; 107(6):2339-45. PubMed ID: 16322474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel type 2A (Group II) von Willebrand disease mutation (L1503Q) associated with loss of the highest molecular weight von Willebrand factor multimers.
    O'Brien LA; Sutherland JJ; Hegadorn C; Benford K; Racz H; Rapson D; Hough C; Lillicrap D
    J Thromb Haemost; 2004 Jul; 2(7):1135-42. PubMed ID: 15219197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms by which von Willebrand disease mutations destabilize the A2 domain.
    Xu AJ; Springer TA
    J Biol Chem; 2013 Mar; 288(9):6317-24. PubMed ID: 23322777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L1503R is a member of group I mutation and has dominant-negative effect on secretion of full-length VWF multimers: an analysis of two patients with type 2A von Willebrand disease.
    Kashiwagi T; Matsushita T; Ito Y; Hirashima K; Sanda N; Fujimori Y; Yamada T; Okumura K; Takagi A; Murate T; Katsumi A; Takamatsu J; Yamamoto K; Naoe T; Kojima T
    Haemophilia; 2008 May; 14(3):556-63. PubMed ID: 18397285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dominant von Willebrand disease type 2A groups I and II due to missense mutations in the A2 domain of the von Willebrand factor gene: diagnosis and management.
    Michiels JJ; van Vliet HH
    Acta Haematol; 2009; 121(2-3):154-66. PubMed ID: 19506362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling ADAMTS13-von Willebrand factor interaction: Implications for oxidative stress-related cardiovascular diseases and type 2A von Willebrand disease.
    Pozzi N; Lancellotti S; De Cristofaro R; De Filippis V
    Biophys Chem; 2012 Jan; 160(1):1-11. PubMed ID: 21937160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Laboratory diagnosis and molecular classification of von Willebrand disease.
    Gadisseur A; Hermans C; Berneman Z; Schroyens W; Deckmyn H; Michiels JJ
    Acta Haematol; 2009; 121(2-3):71-84. PubMed ID: 19506352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mutation distribution in the von Willebrand factor gene related to the different von Willebrand disease (VWD) types in a cohort of VWD patients.
    Yadegari H; Driesen J; Pavlova A; Biswas A; Hertfelder HJ; Oldenburg J
    Thromb Haemost; 2012 Oct; 108(4):662-71. PubMed ID: 22871923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular genetics of von Willebrand disease.
    Mazurier C; Ribba AS; Gaucher C; Meyer D
    Ann Genet; 1998; 41(1):34-43. PubMed ID: 9599650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis of type 2A von Willebrand disease investigated by molecular dynamics simulations and experiments.
    Interlandi G; Ling M; Tu AY; Chung DW; Thomas WE
    PLoS One; 2012; 7(10):e45207. PubMed ID: 23110044
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of von Willebrand Factor--A1 Domain Variants P1266L, H1268D, C1272R, and C1272F in VWD: A Molecular Modeling and Simulation Analysis Approach.
    Doss CG; Ali SK
    Adv Protein Chem Struct Biol; 2016; 102():299-330. PubMed ID: 26827609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural specializations of A2, a force-sensing domain in the ultralarge vascular protein von Willebrand factor.
    Zhang Q; Zhou YF; Zhang CZ; Zhang X; Lu C; Springer TA
    Proc Natl Acad Sci U S A; 2009 Jun; 106(23):9226-31. PubMed ID: 19470641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mutations in von Willebrand factor multimerization domains are not a common cause of classical type 1 von Willebrand disease.
    Keeney S; Cumming A; Hay C
    Thromb Haemost; 1999 Nov; 82(5):1446-50. PubMed ID: 10595636
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new candidate mutation, G1629R, in a patient with type 2A von Willebrand's disease: basic mechanisms and clinical implications.
    Hilbert L; Federici AB; Baronciani L; Dallagiovanna S; Mazurier C
    Haematologica; 2004 Sep; 89(9):1128-33. PubMed ID: 15377475
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case report of two siblings with type 2A von Willebrand disease involving a novel mutation within the calcium-binding site of the A2 domain of von Willebrand factor.
    Igid HP; Thein KZ; Castine M; Quick DP
    Blood Coagul Fibrinolysis; 2019 Jun; 30(4):161-167. PubMed ID: 30762591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Laboratory and molecular characteristics of recessive von Willebrand disease type 2C (2A subtype IIC) of variable severity due to homozygous or double heterozygous mutations in the D1 and D2 domains.
    Michiels JJ; Gadisseur A; van der Planken M; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):111-8. PubMed ID: 19506357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease.
    Meyer D; Fressinaud E; Gaucher C; Lavergne JM; Hilbert L; Ribba AS; Jorieux S; Mazurier C
    Thromb Haemost; 1997 Jul; 78(1):451-6. PubMed ID: 9198195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.